Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | MGAM | O43451 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | SI | P14410 | 4/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15103999 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2662198 | 0.85 | MEN1 (0.51) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL3748590 | 0.84 | MEN1 (0.50) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL3754532 | 0.83 | MEN1 (0.50) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL3756808 | 0.81 | MEN1 (0.54) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL3754553 | 0.80 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2661512 | 0.78 | LMNA (0.53) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL3760687 | 0.77 | MEN1 (0.52) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2660598 | 0.77 | MEN1 (0.60) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2660712 | 0.76 | MEN1 (0.52) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155720-B1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2013-07-17 | — | — | EP | claimed |
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | claimed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | claimed |
| EP-2155720-B1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2013-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, PCK1, GCKR | ALDH1A1 1904/4885KMT2A 1673/4885MEN1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.